Biotech Values

[biotech jim]

Glycomimetics (GLYC) is relatively strong after the pricing of a follow on offering.

Priced at $17 per share

They are a sugar chemistry company, with John Magnani as the guru.

I like their PFE collaboration with the pan Selectin inhibitor Rivipansel for vaso-occlusive crisis in sickle cell disease, and really like (so far) their AML/MM drug candidate GMI-1271, an E-Selectin a Intagonist. 1271 has BTD status from the FDA. These glycomimetics are complex small molecules that, due to their charge characteristics and size, are injectable drug candidates.

I would like to hear more of the Bear case.